We are excited to see the fantastic progress of another Amplitude-founded company with the announcement that Radiant Biotherapeutics, has closed a $35M Series A round co-led by the Bill & Melinda Gates Foundation and Amplitude Ventures.
Radiant is a leader in this next wave of multi-specific antibody approaches. This unique platform is built upon standard monoclonal antibodies while adding in multi-specificity (ability to bind multiple targets with one molecule) and more critically, multivalency (ability to bind the same target with multiple binders). The combination of these two features enables the Multabody to bind targets out of reach of current monoclonal and multispecific approaches and to generate exceptional potency in oncology, immunology and infectious diseases.
Founded in 2020 and emerging out of stealth in 2023, Radiant has rapidly advanced this proprietary platform across multiple “difficult” targets where a majority of antibody approaches have failed. This Series A financing will advance a lead 4–1BB targeting Multabody with a best-in-class efficacy and safety profile into the clinic and will advance other proprietary and partnered programs to IND-enabling studies.
We are extremely proud to see the continued growth of our first launched company and begin to realize its promise of antibody therapeutics. We’re excited to bring on great investors into this round, including the Bill and Melinda Gates Foundation, BDC Thrive Fund, and ABRDN plc, who will help accelerate this company as it continues to scale, unlocking known and new therapeutic targets and combinations for the treatment of diseases with high unmet need.
